Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVDL NASDAQ:CALA NASDAQ:MIRM NASDAQ:OGI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVDLAvadel Pharmaceuticals$21.39-1.1%$21.48$8.19▼$23.57$2.09B1.312.03 million shs35.02 million shsCALACalithera Biosciences$0.00$0.00$0.00▼$0.00N/A-1.05757 shs190 shsMIRMMirum Pharmaceuticals$107.16+4.1%$93.79$42.89▼$112.00$6.53B0.52857,584 shs1.79 million shsOGIOrganigram Global$1.36-1.4%$1.41$1.11▼$2.24$191.44M1.5730,553 shs611,852 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVDLAvadel Pharmaceuticals0.00%0.00%0.00%-1.38%+125.99%CALACalithera Biosciences0.00%-66.67%-66.67%-50.00%0.00%MIRMMirum Pharmaceuticals-6.50%+5.78%+7.61%+2.45%+149.71%OGIOrganigram Global-0.72%-2.13%+0.73%-9.80%+23.77%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVDLAvadel Pharmaceuticals$21.39-1.1%$21.48$8.19▼$23.57$2.09B1.312.03 million shs35.02 million shsCALACalithera Biosciences$0.00$0.00$0.00▼$0.00N/A-1.05757 shs190 shsMIRMMirum Pharmaceuticals$107.16+4.1%$93.79$42.89▼$112.00$6.53B0.52857,584 shs1.79 million shsOGIOrganigram Global$1.36-1.4%$1.41$1.11▼$2.24$191.44M1.5730,553 shs611,852 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVDLAvadel Pharmaceuticals0.00%0.00%0.00%-1.38%+125.99%CALACalithera Biosciences0.00%-66.67%-66.67%-50.00%0.00%MIRMMirum Pharmaceuticals-6.50%+5.78%+7.61%+2.45%+149.71%OGIOrganigram Global-0.72%-2.13%+0.73%-9.80%+23.77%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVDLAvadel Pharmaceuticals 2.00Hold$20.20-5.56% DownsideCALACalithera Biosciences 0.00N/AN/AN/AMIRMMirum Pharmaceuticals 2.93Moderate Buy$136.4228.36% UpsideOGIOrganigram Global 2.33HoldN/AN/ACurrent Analyst Ratings BreakdownLatest CALA, MIRM, OGI, and AVDL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/7/2026MIRMMirum Pharmaceuticals Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$128.00 ➝ $142.005/7/2026MIRMMirum Pharmaceuticals TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$125.00 ➝ $145.005/7/2026MIRMMirum Pharmaceuticals Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingStrong-Buy$165.005/7/2026MIRMMirum Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$185.005/7/2026MIRMMirum Pharmaceuticals EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$138.005/7/2026MIRMMirum Pharmaceuticals Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$136.005/7/2026MIRMMirum Pharmaceuticals Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$112.00 ➝ $129.005/5/2026MIRMMirum Pharmaceuticals Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$130.00 ➝ $140.005/4/2026MIRMMirum Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$150.00 ➝ $175.004/29/2026MIRMMirum Pharmaceuticals Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$125.00 ➝ $130.002/11/2026OGIOrganigram Global ATB Cormark Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Moderate Buy(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVDLAvadel Pharmaceuticals$248.52M8.41N/AN/A$0.77 per share27.78CALACalithera BiosciencesN/AN/AN/AN/AN/AN/AMIRMMirum Pharmaceuticals$521.31M12.43$0.05 per share2,159.32$6.12 per share17.36OGIOrganigram Global$279.99M0.69N/AN/A$1.86 per share0.74Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVDLAvadel Pharmaceuticals-$48.83MN/AN/A356.50N/A-0.11%-0.33%-0.15%N/ACALACalithera Biosciences-$39.65MN/AN/AN/AN/AN/AN/AN/A5/13/2026 (Estimated)MIRMMirum Pharmaceuticals-$23.36M-$0.48N/AN/AN/A-140.24%-10.84%-3.97%N/AOGIOrganigram Global-$17.70M$0.149.8234.38N/A6.03%-15.41%-10.49%5/12/2026 (Confirmed)Latest CALA, MIRM, OGI, and AVDL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026N/ACALACalithera Biosciences-$4.8020N/AN/AN/AN/AN/A5/11/2026Q2 2026OGIOrganigram Global-$0.01N/AN/AN/A$50.78 millionN/A5/6/2026Q1 2026MIRMMirum Pharmaceuticals-$0.3940-$13.43-$13.0360-$13.43$148.21 million$159.88 million2/25/2026Q4 2025MIRMMirum Pharmaceuticals$0.02-$0.11-$0.13-$0.12$141.78 million$148.93 million2/10/2026Q1 2026OGIOrganigram Global-$0.01-$0.02-$0.01$0.11$73.38 million$46.27 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAVDLAvadel PharmaceuticalsN/AN/AN/AN/AN/ACALACalithera BiosciencesN/AN/AN/AN/AN/AMIRMMirum PharmaceuticalsN/AN/AN/AN/AN/AOGIOrganigram GlobalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVDLAvadel PharmaceuticalsN/A2.762.37CALACalithera BiosciencesN/AN/AN/AMIRMMirum Pharmaceuticals0.982.672.55OGIOrganigram GlobalN/A2.731.32Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVDLAvadel Pharmaceuticals69.19%CALACalithera BiosciencesN/AMIRMMirum PharmaceuticalsN/AOGIOrganigram Global34.63%Insider OwnershipCompanyInsider OwnershipAVDLAvadel Pharmaceuticals5.20%CALACalithera Biosciences6.60%MIRMMirum Pharmaceuticals14.36%OGIOrganigram Global0.09%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVDLAvadel Pharmaceuticals7097.66 million92.58 millionOptionableCALACalithera Biosciences603.86 million4.55 millionNot OptionableMIRMMirum Pharmaceuticals14060.98 million52.22 millionOptionableOGIOrganigram Global1,139140.77 million140.64 millionOptionableCALA, MIRM, OGI, and AVDL HeadlinesRecent News About These CompaniesOrganigram Global Sets May 12 Date to Report Q2 2026 ResultsMay 6 at 3:50 PM | tipranks.comOrganigram to Report Second Quarter Fiscal 2026 Results on May 12th, 2026May 6 at 6:11 AM | financialpost.comFOrganigram Global (OGI) to Release Quarterly Earnings on MondayMay 4, 2026 | marketbeat.comHead to Head Review: Organigram Global (NASDAQ:OGI) and Sharps Technology (NASDAQ:STSS)May 2, 2026 | americanbankingnews.comBritish American Tobacco buying at Organigram Global (OGI)May 1, 2026 | theglobeandmail.comOrganigram Global (OGI) Completes EUR 107.3 Million Acquisition of Sanity GroupApril 17, 2026 | finance.yahoo.comOrganigram Global (OGI) Completes EUR 107.3 Million Acquisition of Sanity GroupApril 17, 2026 | insidermonkey.comOrganigram Closes Previously Announced Acquisition of Sanity Group, Private Placement Financing with BAT and ATB Senior Secured Credit FacilitiesApril 15, 2026 | financialpost.comFOrganigram Closes Previously Announced Acquisition of Sanity Group, Private Placement Financing with BAT and ATB Senior Secured Credit FacilitiesApril 15, 2026 | businesswire.comWeekly Roundup on the Cannabis Sector & Psychedelic SectorApril 6, 2026 | finance.yahoo.comIs Organigram Global Inc. (OGI) Among the 11 Best Marijuana Stocks to Buy Right Now?April 1, 2026 | finance.yahoo.comIs Organigram Global Inc. (OGI) Among the 11 Best Marijuana Stocks to Buy Right Now?April 1, 2026 | insidermonkey.comOrganigram Announces Shareholder Approval of Acquisition of Sanity Group GmbH and Results of its Annual General and Special MeetingMarch 30, 2026 | finance.yahoo.comOrganigram Announces Shareholder Approval of Acquisition of Sanity Group GmbH and Results of its Annual General and Special MeetingMarch 30, 2026 | financialpost.comFOrganigram Announces Shareholder Approval of Acquisition of Sanity Group GmbH and Results of its Annual General and Special MeetingMarch 30, 2026 | businesswire.comOrganigram Announces Independent Proxy Advisory Firm ISS Recommends Organigram Shareholders Vote FOR the Acquisition of Sanity Group GmbHMarch 23, 2026 | finance.yahoo.comOrganigram Announces Independent Proxy Advisory Firm ISS Recommends Organigram Shareholders Vote FOR the Acquisition of Sanity Group GmbHMarch 23, 2026 | financialpost.comFOrganigram Announces Independent Proxy Advisory Firm ISS Recommends Organigram Shareholders Vote FOR the Acquisition of Sanity Group GmbHMarch 23, 2026 | businesswire.comOrganigram Sets March 30 Vote on Sanity Group Acquisition and BAT-Funded ExpansionMarch 11, 2026 | tipranks.comOrganigram Announces Mailing of Management Information Circular in Connection with Annual General and Special MeetingMarch 10, 2026 | finance.yahoo.comOrganigram Global Expands FAST™ Innovation Platform with SHRED Shotz, Leveraging SHRED Brand EquityMarch 6, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesCould These 3 New-to-Market Quantum Computing Firms Threaten D-Wave?By Nathan Reiff | April 19, 20263 Overlooked Nuclear Fuel Supply Chain WinnersBy Nathan Reiff | April 26, 2026Credo Stock Flashes Strong Bullish Signal—Upswing Just StartingBy Thomas Hughes | April 21, 2026Palantir Is Down 30%: Noise? Or a Signal to Accumulate?By Chris Markoch | April 28, 2026This AI Lender Has Big Upside Potential—And Big Risks By Peter Frank | April 19, 2026CALA, MIRM, OGI, and AVDL Company DescriptionsAvadel Pharmaceuticals NASDAQ:AVDLAvadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.Calithera Biosciences NASDAQ:CALA$0.0001 0.00 (0.00%) As of 05/6/2026 11:00 AM EasternCalithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.Mirum Pharmaceuticals NASDAQ:MIRM$107.16 +4.23 (+4.11%) Closing price 04:00 PM EasternExtended Trading$107.19 +0.03 (+0.03%) As of 04:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.Organigram Global NASDAQ:OGI$1.36 -0.02 (-1.45%) Closing price 04:00 PM EasternExtended Trading$1.36 +0.00 (+0.37%) As of 05:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Organigram Holdings Inc., through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Edison JOLTS, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative-based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as consumer channels. The company was incorporated in 2010 and is headquartered in Toronto, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SoundHound’s Bottom Is In—Inflection and 50% Upside Ahead? Rocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus AppLovin Pops After Earnings With Growth Catalysts in Sight Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
